The Cardiovascular Risk Factor That Runs in Families — and That Most Doctors Never Check
Dr. Jeff Kindred, DOA patient came in not long ago because his father had a heart attack at 54. Not a massive one — but enough to put him in the cath lab. The patient was 47, healthy by every standard measure: normal weight, non-smoker, exercised regularly, ate reasonably well. LDL of 98. Blood pressure fine. Every number his previous doctor had looked at was reassuring.
He wasn't exactly worried. But he wasn't not worried either. His father had looked healthy too.
We ran a comprehensive lipid panel — the kind that goes beyond what a standard cholesterol check includes. One number came back elevated: his Lp(a).
It explained a lot.
He's not alone. Several patients in our practice have come back with elevated Lp(a) levels. Most had no idea. Their standard labs looked fine. Nobody had ever checked.
What Lp(a) Actually Is
Lipoprotein(a) — pronounced "L-P-little-a" — is a particle that looks a lot like LDL on the surface. Same basic structure. But it carries an extra protein called apolipoprotein(a) that makes it stickier, more inflammatory, and harder for the body to clear.
The trouble it causes is twofold. Like LDL, it penetrates artery walls and drives plaque formation. But it also interferes with clot breakdown — so elevated Lp(a) raises your risk not just of atherosclerosis building up over decades, but of acute clotting events on top of existing plaque. Heart attacks. Strokes. Aortic stenosis, in some cases.
Here's the part that makes it different from most cardiovascular risk factors: diet doesn't move it. Exercise doesn't move it. Statins — the most-prescribed lipid drugs in the world — lower it maybe 10-15% at best. That's not nothing, but if your levels are significantly elevated, it's rarely enough to matter clinically. You're largely born with the Lp(a) level you'll carry your whole life.
That's what makes family history such a relevant clue.
The Testing Gap
For most of the history of cardiovascular medicine, Lp(a) was something cardiologists knew about but couldn't do much about. The logic was circular but not entirely wrong: if a test doesn't change management, why run it?
That reasoning was defensible — barely — when the only tools available were statins and lifestyle. It's much harder to defend now, and I'd argue it was always underselling what the information is worth.
About one in five people worldwide has elevated Lp(a). That's not some rare genetic variant. That's a common, measurable risk factor sitting in the background of tens of millions of people who've been told their cholesterol looks fine. People with very high Lp(a) levels carry 2.5 to 3 times the cardiovascular risk of those with normal levels — independent of LDL, blood pressure, smoking status, and every other traditional marker we track. It's its own signal, and it's not a small one.
The test is a single blood draw. It's inexpensive. The result doesn't change over time, so you only need to do it once. And knowing it changes how aggressively we need to manage everything else around it.
If cardiovascular disease runs in your family — especially before age 60 — this should be part of your workup. Full stop. Same if you've had a cardiovascular event that your traditional risk factors don't fully explain. Same if you're doing a thorough longevity-focused panel and want an accurate picture rather than the abbreviated version most annual physicals provide.
The argument for not testing has always been thin. It's getting thinner.
Why This Is a Particularly Timely Conversation
Here's what makes Lp(a) worth writing about right now: for the first time, there are drugs in late-stage development that reduce it dramatically. Not the 10-15% you get from statins. We're talking 85-96% reductions.
Three are the ones to watch closely.
Olpasiran, developed by Amgen, is a small interfering RNA — it essentially turns off Lp(a) production at the level of the gene. In the OCEAN(a)-DOSE trial, patients getting 75 mg every 12 weeks saw greater than 95% reductions in Lp(a). The ongoing OCEAN(a) outcomes trial will tell us whether that reduction translates into fewer heart attacks and strokes. Results are expected in the next few years.
Pelacarsen, from Novartis and Ionis, works through similar RNA-based machinery. Its Phase 3 HORIZON trial enrolled 8,323 patients with established cardiovascular disease and elevated Lp(a) — results are expected in 2026. That will be the first large-scale test of whether lowering Lp(a) actually changes outcomes, and cardiology will be watching closely.
Muvalaplin, from AstraZeneca, is the interesting outlier: it's an oral pill, not an injection. Phase 2 showed 86% reductions in intact Lp(a). A Phase 3 trial is now enrolling over 10,000 patients. If the effect holds, an oral option changes the practical picture considerably for patients who would otherwise need injections every few months.
One honest caveat worth naming: these drugs reduce Lp(a) levels. What we don't yet have is definitive proof they reduce cardiovascular events. That's what the outcomes trials are designed to show. The biology is compelling and most cardiovascular researchers expect the answer to be yes — but medicine has been humbled before by surrogate markers that looked better than they were, and I'd rather give you the accurate version of where we are than the oversimplified one.
That said: we're closer than we've ever been to having a real treatment for something that has been essentially untreatable for decades. That changes the calculus on testing.
What We Do With It Now
For patients who come back with elevated Lp(a) today, the clinical response is to manage everything around it more aggressively. LDL targets come down — often below 70 mg/dL, sometimes lower. Blood pressure control gets prioritized. We're watching ApoB alongside LDL, because particle count matters more than cholesterol mass when underlying risk is already elevated. (We've written more about that here.)
We can't fix the Lp(a) itself right now. But knowing it's there changes how tight we have to be on the things we can fix.
The patient I mentioned at the start — the one whose father was in the cath lab at 54 — now knows something important about his own biology. His LDL is going lower than it would have otherwise. We're tracking his ApoB. He's the kind of patient who will be among the first in line when one of these therapies clears an outcomes trial.
He came in because he had a nagging feeling that his standard workup wasn't telling him everything. He was right.
That's really what this kind of medicine is about — not chasing perfect numbers, but making sure you actually have the full picture. Most of the time, the whole game in preventive cardiology is finding the things worth finding while there's still time to act on them.
If heart disease runs in your family, Lp(a) is worth knowing.
If you're interested in concierge medicine and want to know where you actually stand — Lp(a) included — schedule a consultation with Dr. Kindred here.
Related posts: The Silent Damage of Blood Pressure and Cholesterol — And Why Waiting 10 Years Is Too Late | VO₂ Max: The Most Powerful Number You're Not Tracking | Medicine 3.0 + Concierge Care: Why Your Relationship With Your Doctor Matters More Than Ever
References
- Nordestgaard BG, et al. Lipoprotein(a) as cardiovascular risk factor: current status. European Heart Journal. 2010;31(23):2844-2853. https://pubmed.ncbi.nlm.nih.gov/20965889/
- Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. Journal of the American College of Cardiology. 2017;69(6):692-711. https://pubmed.ncbi.nlm.nih.gov/28183512/
- O'Donoghue ML, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. New England Journal of Medicine. 2022;387:1855-1864. https://pubmed.ncbi.nlm.nih.gov/36342113/
- Tsimikas S, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. New England Journal of Medicine. 2020;382:244-255. https://pubmed.ncbi.nlm.nih.gov/31893580/
- Nissen SE, et al. HORIZON trial (pelacarsen). ClinicalTrials.gov NCT04023552. https://clinicaltrials.gov/study/NCT04023552
- Nicholls SJ, et al. Muvalaplin for lowering of lipoprotein(a). JAMA. 2023;330(22):2170-2176. https://pubmed.ncbi.nlm.nih.gov/37870789/
- Reyes-Soffer G, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(1):e48-e60. https://pubmed.ncbi.nlm.nih.gov/34647487/
Dr. Jeff Kindred is a concierge physician in Nashville, TN, practicing longevity-focused preventive medicine at Hi, Finch Health.